Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Colorcon
Cerilliant
Queensland Health
Harvard Business School
Medtronic
Daiichi Sankyo
McKesson

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,911,217

« Back to Dashboard

Which drugs does patent 6,911,217 protect, and when does it expire?

Patent 6,911,217 protects DETROL LA and is included in one NDA.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-eight patent family members in forty-four countries.
Summary for Patent: 6,911,217
Title: Controlled release bead, a method of producing the same and multiple unit formulation comprising it
Abstract:A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
Inventor(s): Gren; Torkel (Kalamazoo, MI), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE), Wald; Randy J. (Portage, MI)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/763,281
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 6,911,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,911,217

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/SE99/01463Aug 26, 1999
PCT Information
PCT FiledNovember 11, 1999PCT Application Number:PCT/SE99/02052
PCT Publication Date:May 18, 2000PCT Publication Number: WO00/27364

Non-Orange Book US Patents Family Members for Patent 6,911,217

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,770,295 Therapeutic formulation for administering tolterodine with controlled release ➤ Sign Up
7,008,637 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder ➤ Sign Up
6,517,864 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder ➤ Sign Up
6,630,162 Pharmaceutical formulation and its use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,911,217

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1323 ➤ Sign Up
African Regional IP Organization (ARIPO) 1529 ➤ Sign Up
Argentina 027815 ➤ Sign Up
Argentina 029311 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
Daiichi Sankyo
Accenture
Chubb
Chinese Patent Office
Covington
Cantor Fitzgerald
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.